Results 181 to 190 of about 90,167 (303)

AB0751 The differences and similarities between patients and physician global assessment in patients with psoriatic arthritis [PDF]

, 2017
Kemal Nas, Erkan Kılıç, Remzi Çevik, AZ Dagli, Gamze Kılıç, Sinem Sağ, Ayhan Kamanlı, İbrahim Tekeoğlu   +7 more
openalex   +1 more source

Prevalence of vasculitis, systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis, idiopathic inflammatory myopathies and spondyloarthritis in Australia: a systematic review and meta‐analysis

Internal Medicine Journal, EarlyView.
ABSTRACT Background Systemic autoimmune rheumatic diseases (SARDs), including vasculitis, systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SSc), idiopathic inflammatory myopathies (IIM), spondyloarthritis (SpA), Sjogrens disease (SjD) and mixed connective tissue disease (MCTD), are rare but associated with substantial ...
L. Roper, E. Cameron, T. Yu, N. Li, M. Parker, N. Nassar, M. Nikpour   +6 more
wiley   +1 more source

Sex differences in serum proteomic profiles in psoriatic arthritis. [PDF]

Rheumatology (Oxford)
Dang S, Li X, Diao L, Piguet V, Croitoru D, Wither J, Jurisica I, Chandran V, Eder L.   +8 more
europepmc   +1 more source

FRI0361 CARTILAGE DEGRADATION IN PSORIATIC ARTHRITIS IS ASSOCIATED WITH INCREASED SYNOVIAL PERFUSION AS DETECTED BY MAGNETIC RESONANCE IMAGING [PDF]

, 2020
Philipp Sewerin, Daniel B. Abrar, Anja Müller‐Lutz, Miriam Frenken, Karl Ludger Radke, Stefan Vordenbäumen, M. Schneider, Benedikt Ostendorf, Christoph Schleich   +8 more
openalex   +1 more source

Mitochondrial Activity Regulates Human T Helper 17 Differentiation and Function

Immunology, EarlyView.
Naïve CD4+ T cells differentiating into RORγt+IL‐17A+ Th17 cells are characterised by a shift from glycolysis to oxidative phosphorylation. Early‐stage cells favour glycolysis, whereas later‐stage cells with hyperpolarised mitochondrial membrane potential (ΔΨ) rely more on oxidative phosphorylation, show increased activation, and differentiate more ...
Xinlai Chen, Theodoros Ioannis Papadimitriou, Anne H. G. van Essen, Britt van Brunschot, Monique M. Helsen, Annet Sloetjes, Elly L. Vitters, Werner J. H. Koopman, Peter M. van der Kraan, Arjan P. M. van Caam, Marije I. Koenders   +10 more
wiley   +1 more source

Obstructive sleep apnea in psoriatic arthritis: A polysomnography-based Evaluation. [PDF]

Medicine (Baltimore)
Mustafa M, Attar S, Kanbr O, Bawazir Y, Bamagoos AA, Boudal A, Alhejaili F, Wali S.   +7 more
europepmc   +1 more source

Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019

, 2020
Bathon, J., Breedveld, F., Burmester, G., Bykerk, V., Crofford, L., Cronstein, B., Dougados, M., Furst, D., Kalden, J., Mariette, X., Mease, P., Melchers, F., Rosenbaum, J., Sieper, J., Smolen, J., Weinblatt, M., Winthrop, K.   +16 more
core   +1 more source

Inflammatory osteolysis: A conspiracy against bone [PDF]

, 2017
Abu-Amer, Abu-Amer, Anton, Bardin, Beranger, Chen, Christo, Claro, Cobelli, Coll, Dapunt, Deborah V. Novack, Dewhirst, Gabriel Mbalaviele, Georg Schett, Gravallese, Harre, Josse, Jovanovic, Kollias, Lukens, Maitra, McCall, Mukai, Negishi-Koga, Osta, Ozen, Pasco, Robaszkiewicz, Rubbert-Roth, Sanchez, Scianaro, Sharma, Steven L. Teitelbaum, Van Hauwermeiren, Wang, Zaki   +36 more
core   +2 more sources

A decade of pharmacovigilance in France: Immune checkpoints join the list of usual suspects for drug‐induced immune haemolytic anaemia

British Journal of Haematology, EarlyView.
Guillaume Brenac, Anne Dautriche, Romane Freppel, Anthony Facile, Bruno Revol, Mathilde Beurrier, Bernard Bonnotte, Sylvain Audia   +7 more
wiley   +1 more source

Improvement and maintenance of clinical outcome assessments in atopic dermatitis with amlitelimab

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Clinical outcome assessments (COAs) were evaluated in the STREAM‐AD phase 2b trial investigating amlitelimab in patients with moderate‐to‐severe atopic dermatitis. Amlitelimab improved COAs at Week 24 versus placebo. The majority of patients achieving clinically meaningful COA improvements at Week 24 who continued/withdrew from amlitelimab maintained ...
Andrew Blauvelt, Raj Chovatiya, Joseph F. Merola, Stephan Weidinger, Ken Igawa, Ella Brookes, Christine Weber, Jennifer Wang, Cori Gray   +8 more
wiley   +1 more source